BiopharmaTrend.com

Evaxion Biotech

Evaxion Biotech

Private company
EVAXION BIOTECH

Using cutting-edge immunology, bioinformatics, and machine learning methods, Evaxion Biotech is discovering and developing 'best in class’ vaccines for infectious diseases and cancer at an unprecedented rate. We have constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, PIONEER and EDEN. Using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. EDEN enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while PIONEER has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them.


Founded
2008
Status
Private company
Geography
Denmark based
Funding
$17 M
Patents
14
Research papers
10

Products

PIONEER

PIONEER is Evaxion’s immuno-oncology platform focused on developing personalized cancer immunotherapies. It uses sophisticated algorithms to identify and select those …

Read more

EDEN

EDEN has the ability to identify novel, bacterial vaccine antigens that trigger robust, protective immune responses against a broad range …

Read more

Services

No services posted yet


This data is part of our proprietary analytics report:

This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page